I'll research MRK before writing the preview. Let me gather recent earnings materials, filings, and news.Let me read the most recent earnings materials and the recent investor event, plus recent news.Let me pull the recent investor event, broader July news, and stock price context.# Merck & Co. (MRK) — Q2 2026 Earnings Preview
Consensus for the quarter is roughly $16.33B in revenue (~+3–3.4% YoY) against a Q2 2025 base of $15.81B, with a reported EPS of about –$0.25. The headline loss is optical, not operational — it reflects a one-time R&D charge from the Terns Pharmaceuticals acquisition (~$5.8B, or ~$2.35/share), which was structured as an asset acquisition and expected to close in May. Underlying ex-charge earnings power remains solidly positive.
Key framing: This is the second consecutive quarter where a large BD-driven charge distorts GAAP/non-GAAP EPS (Q1 carried a $9.0B / $3.62 Cidara charge). Investors should look through the print to (a) organic revenue momentum, (b) whether full-year guidance is raised/narrowed again, and (c) pipeline execution into a heavy H2 catalyst calendar.
MRK enters the print with real momentum. Shares are up roughly 20% YTD (~$106 → ~$128), meaningfully outpacing the healthcare sector (XLV ~+4% over the same window). The stock bottomed near $110 in late April (post-Q1, when the Cidara charge and Gardasil weakness weighed), then rallied hard from late June (~$120 → ~$129) through July on improving sentiment around Keytruda durability and pipeline optionality.
Implication: Expectations have reset higher. After a ~20% run, the bar for a positive reaction is now elevated — clean organic beats plus a guidance raise may be needed to sustain the move, while any softness in Gardasil or a cautious H2 tone could trigger profit-taking.
Everything about the MRK thesis orbits the same question — can the company replace Keytruda ahead of its 2028 patent cliff? Keytruda is the best-selling drug in the world (~$32B in 2025, ~$8.0B in Q1 2026), and U.S. patents begin eroding in 2028.
Management's answer is a portfolio transformation: 20+ new product launches with a stated >$70B revenue opportunity by the mid-2030s. Watch for updated commentary on:
Modeling nuance to flag: Management explicitly warned that Q1 Keytruda benefited by ~$250M from U.S. wholesaler purchase timing, with a corresponding headwind coming in Q3. Q2 Keytruda growth should be judged against that context.
At Q1, MRK raised and narrowed FY26 guidance to revenue $65.8–67.0B and non-GAAP EPS $5.04–5.16 (including the $3.62 Cidara charge, ~1pt FX tailwind). Critically, this guidance excludes Terns (~$2.35/share charge + ~$0.12 dilution from financing/TERN-701 investment).
What to watch: - Does management raise/narrow again given FX tailwinds and launch momentum? - Does the Terns charge now get formally folded into the guide (it closed in May)? - SG&A was flagged to step up in H2 to support launches — watch operating-expense cadence. - Reiteration of ~$3B buybacks and the dividend commitment.
MRK framed 2026 as a "particularly robust period of Phase 3 readouts." Near-term regulatory/data events to listen for on the call:
| Catalyst | Timing | Note |
|---|---|---|
| KEYTRUDA + Padcev, MIBC (KEYNOTE-B15) | PDUFA Aug 17 | Just days after earnings — potential 12th earlier-stage indication |
| WELIREG + Lenvima, RCC (LITESPARK-011) | PDUFA Oct 4 | |
| I-DXd, ES-SCLC (Daiichi collab) | PDUFA Oct 10 | |
| WINREVAIR HYPERION label update | PDUFA Sept 21 | |
| Enlicitide (oral PCSK9) | H2 2026 approval via CNPV | 3 positive Phase 3 CORALreef readouts; large primary-cardiology TAM |
| Tulisokibart (TL1A) | 2026 | Phase 3 ATLAS-UC (ulcerative colitis) + Phase 2 fibrosis data |
| WELIREG adjuvant RCC (LITESPARK-022) | PDUFA was June 19 | Look for approval confirmation |
Mind the misses too: Q1 brought setbacks — LITESPARK-012 (RCC triplet), KEYNOTE-975 (esophageal) and KEYNOTE-866 (MIBC) all failed primary endpoints. Management downplayed read-through risk to ongoing WELIREG studies, but the pipeline is not without stumbles.
Notably, MRK held an HIV investor event on August 3 (the day before earnings) recapping AIDS 2026 data. Positives to carry into the call: - Positive Phase 3 ISLEND-1/-2 (islatravir + lenacapavir, w/ Gilead) — non-inferior efficacy, >90% viral suppression, no treatment-emergent resistance, high patient satisfaction — supporting the first once-weekly oral HIV regimen. - IDVYNSO (doravirine/islatravir) — newly FDA-approved daily oral; early launch underway. - A framed >$5B (non-risk-adjusted) HIV opportunity by the mid-2030s across treatment (isla/lena, islatravir/ulonivirine) and monthly-oral PrEP (MK-8527).
Economics reminder: Gilead/Merck share global costs 60/40; on long-acting orals, Gilead leads U.S. commercialization, Merck ex-U.S., with revenues split 50/50 up to ~$2B then 65/35 Gilead thereafter.
Expect a GAAP loss driven by the Terns charge that is not a fundamental negative — the story is organic growth ex-Keytruda-timing and the guidance trajectory. The three swing factors for the stock's reaction:
With the stock up ~20% YTD and sentiment improving, the risk/reward is more balanced than it was in April — clean execution and a confident H2 catalyst narrative are likely needed to extend the rally, while a Gardasil miss or cautious tone are the most probable sources of downside.
Note: This preview is based on Merck's Q1 2026 earnings materials (reported April 30, 2026), the August 3 HIV investor event, recent news, and market data. It is for informational purposes and is not investment advice.